Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 6Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 7Sarcoma 3Thyroid Neoplasms 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Extensive Stage 1Proteinuria 1Platinum-resistant Ovarian Cancer (PROC) 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Melanoma 1Limited Stage Small Cell Lung Cancer 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Specimen Handling 9Magnetic Resonance Spectroscopy 9Drug Therapy 7Carboplatin 7osimertinib 6Tomography, X-Ray Computed 5Pemetrexed 5Educational Status 5Interviews as Topic 4Early Intervention, Educational 4Cisplatin 4Blood Specimen Collection 4pembrolizumab 3cemiplimab 3atezolizumab 3Radiosurgery 3Methods 3Injections 3Etoposide 3durvalumab 2anlotinib 2aflutinib 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy 2Radiation 2PM 01183 2Observation 2Nivolumab 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Neoplasms × anlotinib × Clear all
NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Lung Neoplasms

NCT06048315 2023-09-21

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Qianfoshan Hospital

Phase 3 Not yet recruiting
52 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡